Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals
News Mar 26, 2014
Courtagen Life Sciences has announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders.
Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
“The genetic profiling of patients is expected to elucidate important information beneficial to Raptor’s clinical trial for RP103,” said Brian McKernan, CEO of Courtagen.
McKernan continued, “We are pleased to work with Raptor Pharmaceuticals and believe that Courtagen’s mtSEEK® and nucSEEK® Next Generation Sequencing tests offer the most comprehensive mitochondrial analysis for such clinical trial work.”
CRISPR Used to Prevent Development of Angiogenesis of the RetinaNews
Powerful new technology may lead to novel therapies to prevent vision loss, blindness in those with diseases of the retina.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018